Lung Biomarkers: a new route for distinguishing pulmonary hypertension due to HFpEF from pulmonary arterial hypertension

Despite thoughtful evaluation by echocardiography and advanced [ [1] Jellis C.L. Park M.M. Abidov A. et al. Comprehensive echocardiographic evaluation of the right heart in patients with pulmonary vascular diseases: the PVDOMICS experience. Eur. Heart J. Cardiovasc. Imaging. 2021; Crossref PubMed Scopus (2) Google Scholar ] imaging are pillar for phenotyping pulmonary hypertension (PH) and the right heart, the definitive diagnosis of any WSPH classified PH clinical groups requires a right heart cathetherization study [ [2] Vachiery J.L. Tedford R.J. Rosenkranz S. et al. Pulmonary hypertension due to left heart disease. Eur. Respir. J. 2019; 53 Crossref PubMed Scopus (262) Google Scholar ]. Plasma tumour and metabolism related biomarkers AMBP, LPL and Glyoxalase I differentiate heart failure with preserved ejection fraction with pulmonary hypertension from pulmonary arterial hypertensionInternational Journal of CardiologyVol. 345PreviewDiscrimination of heart failure with preserved ejection fraction with pulmonary hypertension (HFpEF-PH) from pulmonary arterial hypertension (PAH) is crucial for clinical management but may be challenging due to similarities in clinical and comorbid characteristics. We aimed to investigate tumour and metabolism related proteins in differentiating HFpEF-PH from PAH. Full-Text PDF Open Access